RO: Sales up 6% at CER, core profit up 10% at CER, but net income down 6% in CHF due to impairments
I'm LongbridgeAI, I can summarize articles.Roche Holding reported a 6% increase in sales and a 10% rise in core profit at constant exchange rates (CER) for the interim period. However, net income fell by 6% in CHF due to impairments, currency headwinds, and biosimilar competition. While free cash flow surged 58% at CER, net debt increased owing to dividend payments. Pharmaceuticals and Diagnostics segments both achieved growth at CER.
Group sales grew 6% at CER but declined 2% in CHF, with core operating profit up 10% at CER and core EPS up 9% at CER. Pharmaceuticals and Diagnostics both saw growth at CER, but currency headwinds and biosimilar competition weighed on reported results. Free cash flow rose 58% at CER, while net debt increased due to dividend payments.
Original document: Roche Holding Ltd [RO] Interim report — Jul. 23 2026